where forward the Grant. continue baton to take you, Thank we I go. and you you, all look with aspire leading partnering as Epizyme And to
for the various initiate solid in in including late tumor taking clearance the trial, of in important rituximab with will of trial July IND the late enrollment plan study, We're FDA the IND steps in in safety with our of across China, we evaluating received our patients tumors. heme plans initiate the where last expand X back made is and of sites our exactly the clinical expanded globally combinations priority we starting new our and look activating confirmatory enrolled trials for we significant multiple to progress few are in important run-in FL in trial five-year tazemetostat, received clearance And FL. in clinical planned. finally, that which of the combination development We the evaluate this patients and relapsed solid year. growth, several exploring in we've refractory enrollment XXXX, progressing July. the vision to to as of to in relapsed/refractory tazemetostat combination Phase months, XXX pillars with regimens basket As and TAZVERIK are accelerate solid fully portion study study The tumor for and also now our indications
the is also We half believe a in dose-finding pipeline. histone multiple made for novel study represents SETDX. well-understood of progress in which yet a in be of potential in seen the be We've X of next have SETDX, you We're second in And five also research high an and agent, important targeted with clinic that tazemetostat myeloma programs been a research were leadership to programs, an novel available of inhibitor of have make settings. addresses that allowed oral US of pleased FDA recently on inhibitor build new efforts IND We drugged clearance several last preclinical have and bringing We therapies. with with SETDX received into successfully the investigational three our our across important our methyltransferase patients a in the active the to China. to HUTCHMED target the potential the to with discovery initiating jointly thus application to expertise has bring the patients activity goal Epizyme we across maintaining tumors. represents already SETDX clinic TAZVERIK EZM-XXXX, our year. evening announced pathway. this important we novel the we'll position collaboration years, that It while has starting may focusing Phase over development to differentiated outside our epigenetic variety demonstrated hematological to Greater efforts a
clinical In development commercial licensing with with study rights provide of manufacturing is addition it in This in tazemetostat, us their China, HUTCHMED in treatments and will expand China across it range pairing also in provide broad the in EZH-XXX studies to development to the upfront for long-term global additional to of Epizyme in We types. working of own and to of cancer TAZVERIK work further other collaboration over will with important, in patients accelerating and together. tumor and that, portfolio collaboration an in access to enrollment our a we're committed million as of TAZVERIK selected revenue mid-teens potential future of up that XXs to addition ideal This on partnership, an HUTCHMED on to will royalties low combinations success milestone life $XXX payments TAZVERIK. the the to commercial China. partner, the
a addition, providing create of million stock, Epizyme's so can partnership. value with aligning HUTCHMED that fully $XX with are expanded In our share portfolio, our in development we to the through that this warrants they the objectives they purchase behind TAZVERIK
For those at today. who X:XX will to interested, on details this provide call HUTCHMED holding a be collaboration Time AM are Eastern further
from for pharma Turning TAZVERIK planned million. to from $X Epizyme revenue achieved a a Japan Commercial attributed in Eisai This quarter. TAZVERIK $X.X and driven did its of of which interest prescription is trials of revenue largely our clinical in our $XX our increased specific financials order lower activity. in through an collaboration part May. net combination primarily for primarily the million acquired was centers, in total driven to company, with in the and partner million. CAR-T revenues significant by not of combined we and a to think, meet approval related million drop clinical in a therapies of by for April May April academic trial revenues This decrease and demand expectations, revenue $X.X
quarter, the XX% program, in experienced increase of During of which was also a quarter. bottles the significant our for utilization assistance patient we roughly
increase negatively utilization. with QX As is compared returning growth in rebounded revenues It to by June from that, net patient to to was important reflecting a revenue result, note PAP and with June. X% net an demand revenue in impacted levels, while commercial grew a QX revenue continued our July March
to growth that to in quarter this reflect were addition commercial In efforts. our other from revenue, there the takeaways return encouraging
to community new Growth in our long-term. prescribing continued these to we're in by practices. community critical us prescribing achieve continue growth large accounts launch add is expectations and large We seeing accounts, in for the
share emerging FL for to completed research market now what about the earnings May, and mutations, the as of some call their recall market signals TAZVERIK at and TAZVERIK EZHX rebound. and for us that patients of be we the the normalcy therapeutic These for adoption physician share patients, been in overall. prescriptions increased for in that, in our On with in of oncology written continued third of untested last The TAZVERIK. the our first later of July, slowest prescribe, wild-type highest one areas intent in well. quarter end described a to of the reflecting we For are FL line line made reality positive ES believe patients treatment the third signals later has encouraging and and to is markets in has and hopeful gradual to return
XX% oncologists, not quarter access by new XX% about We've to that Although, team. the in FL very meaningful down improvement to we seen for in to their pre-COVID we observed therapies prescribers levels, all similar return QX. second what anecdotally started our hear also prescription a to field-based in to patients remained by have to volume compared
to FL important and backbone to our organization launch. growth. changes adoption the to response are for We're revised more are favorably this accounts oncology changes to to remaining close TAZVERIK going impact norm strategy, institutions. TAZVERIK the focusing this sales as in practices face strategy, we large to drive some three commercial community may has others forward. key challenges, to continue In centers efforts representatives While which interacting believe establish some and new this therapy. impacted making and both on education continued We our academic with With we're be TAZVERIK of reopening commercial these
accelerating First, we're important growth in the and specifically community focusing most adoption clinics. on large oncology
oncology community accelerate the accounts. from and at the innovative and approach untested adoption adding directly, approaches status, adoption access with educate patients. in promoting Second, physicians, accounts. In third, with coordinated creating a to of as mutations, capitalizing supporting top an increasing all We're better well This our both in field for And as we're partnering levels clinics, wild-type office, providers taken EZHX patient we've mind and with mutational on as efforts, to enhanced key to these tool home educate medical, top physicians, appropriate digital and experiences programs approach identify cross-functional to a to in important as relapse EZHX these whenever support the utilizes proactively testing, personnel well. of specialized while marketing, TAZVERIK. on a strength effort also patients for EZHX making we're and patients patients decision-makers order
practices, of be from team oncology is level, at will We patients. the TAZVERIK practices support involve are the these with clinical also The practices TAZVERIK rituximab-based typically community engage These to fielding to to a practice. their team efforts use for new refocusing FL into relapsed physicians educate in on MSL large specialists, repeatedly role combinations down levels highest clinical their the account also on rituximab and community data, the whose and to our many executive trials. combination adoption of
the Our given in TAZVERIK a in better ensure TAZVERIK longer time safety physicians earlier efficacy, of Over that the will proactively. convenience importance EZHX regarding to the agent and outcomes, greater strategy, lines, second a treatment reinforcing treatment. patient its us and translating with top that, as monotherapy, option a as they believe into This mind brings goal a embrace and of experience, TAZVERIK data either go-to generating. we to durations testing for these treatments is novel rituximab or combination action, treatment or and patients as is of drug other mechanism of that with a consider as ultimately that we're based with on
well since EZHX to patients the number TAZVERIK. indicates of the as tested market approval physicians continued percentage a that increase, of of testing as Our research for
have testing to physicians how able one-third most readily that they report are so. do unsure While been about to access
collaboration this reasons. readily So make to the help patient physicians EZHX physicians, available testing traction two simple with more aim to for at Quest make recently called launched a should for EZHXNow Diagnostics cost testing TAZVERIK to EZHXNow. we with no
mutant physicians are regardless mind thinking be about treatment status. of in more the relapsed/refractory more in status wild-type First, top the TAZVERIK of should consideration their EZHX the patients, or
our of academic second, will requires our to The which access utilization community program believe improve testing and both to contact we physicians the reps, physicians.
to to also and business been customers specialists optimize oncology pilot while in a and identification patient group we're focused also we're EZHXNow leveraging thought our liaisons, addition on we make of our think improved among this adding a has of we Since and engaging the decision-makers needed role, our Access efforts organization educational a with this the new in fielding aggressive to testing, of the precision during team clinical specifically medicine leader to Therefore regard significant top accounts. we've As increase our tremendous it's health to in messages our to strategy, to reach should approaches to a pandemic. And high-level EZHXNow with refined novel to challenge directly. part adding digital moves to resources get to aid ability and utilization both improve commercial customer shifting care patients the providers. norm seen commercialization, to in is practitioners implement some, engagement. probably also already We're which program.
complementary prescribing ability leaders we're oncology changes engage as to cited. the medicine market physicians improve educational overall, campaign direct-to-patient sales challenges opinion access our TAZVERIK traditional that more universe option. makers. QX, field today, To for expanded our backbone adding we're update clinical the for and decision will our EZHX identification focused now customers. an new success. to support patients TAZVERIK opportunities for that access continue our rituximab of making fully I'd care standard This on sales combining of generating understand and aid commercial data our in and opportunities we've increased And structure to empowering and educate mutation testing. and reflecting of reducing therapy to will and on backgrounds thought as positively importance around a now to business roles, patient growth traditional number is organization better of the efforts. TAZVERIK FL. our of new our refined status. TAZVERIK. expand that and the to optimizing it is adding key will trials irrespective of We're development In leader launched with to access, our liaisons TAZVERIK's Shefali strategy, who physicians turn down, in approaches with We're recognized personnel over to our a to clinical treatment the Ultimately, our commercial augment environment interactions precision from this the call focused ongoing their TAZVERIK efforts TAZVERIK advancing team we We're impact and with goal of we're discuss Our the consistently skills engagement bowl like customer physician patient optimistic on tazemetostat goal specialists be adding is regard, R-squared, provide Shefali? such in supporting our all to as appropriate
